Other languages Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.585 ^USD	+0.42%		-6.64%	-83.68%

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Tenax Therapeutics Secures Global Rights for Levosimendan	Feb. 20
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	Feb. 20
Top Midday Decliners	Feb. 08
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	Feb. 08
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	Feb. 08
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	Feb. 08
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	Feb. 07
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06
Sector Update: Health Care	Feb. 06
Top Midday Gainers	Feb. 06
Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer	Jan. 12
Tenax Therapeutics to Implement 1-for-80 Reverse Stock Split	Dec. 29
Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board	Nov. 17
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	Nov. 13
Sector Update: Health Care	Nov. 13
Top Midday Gainers	Nov. 13
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure	Nov. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Other languages

Filters